{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:44:29Z","timestamp":1787010269872,"version":"build-2736575974"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVES:<\/jats:title>\n                    <jats:p>Children on extracorporeal membrane oxygenation (ECMO) are at high risk of infection that may worsen prognosis. Even though treatment with beta-lactam antibiotics is frequent, dosing is not adapted to altered pharmacokinetic and pharmacodynamic characteristics of children on ECMO. There is, therefore, a risk of inadequate drug levels when using standard dosing. In this study, we aimed to describe beta-lactam exposures of children on ECMO using current dosing and to identify factors associated with inadequate exposure. The optimal pharmacokinetic\/pharmacodynamic target was considered as a plasma concentration four times above the minimum inhibitory concentration throughout the dosing interval target.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DESIGN:<\/jats:title>\n                    <jats:p>Two-center retrospective cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SETTING:<\/jats:title>\n                    <jats:p>Two PICUs in Paris, France.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS:<\/jats:title>\n                    <jats:p>Children (from birth to 18 yr) undergoing venovenous or venoarterial ECMO, from 2018 to 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>INTERVENTIONS:<\/jats:title>\n                    <jats:p>None.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MEASUREMENTS AND MAIN RESULTS:<\/jats:title>\n                    <jats:p>\n                      There were 57 patients who received 11 different beta-lactams, with 226 plasma concentrations analyzed. A total of 32 infections were documented. Overall, 133 of 226 concentrations (58.8%) were insufficient, primarily in samples from children younger than 28 days (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.035), with low body weight (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.013), or in instances of hypoalbuminemia (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.011) and increased renal clearance (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.032). Supratherapeutic concentrations were observed in 25 of 226 samples (11.1%), associated with being taken from patients with renal impairment (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>In this retrospective cohort of pediatric ECMO cases, there is an associated risk of underexposure when prescribing conventional dosing of beta-lactams, which are likely associated with renal impairment and fluid overload. Prospective testing of therapeutic drug monitoring combined with pharmacokinetic\/pharmacodynamic models should be tested as a risk-reduction strategy in this vulnerable population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/pcc.0000000000003605","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T10:02:43Z","timestamp":1728295363000},"page":"1127-1137","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Beta-Lactam Antibiotic Exposure During Pediatric Extracorporeal Membrane Oxygenation: Retrospective Cohort Analysis of Drug Levels Using Standard Dosing, 2018\u20132020"],"prefix":"10.1097","volume":"25","author":[{"given":"Alice","family":"Marsaux","sequence":"first","affiliation":[{"name":"Service de R\u00e9animation et surveillance continue m\u00e9dicochirurgicales, H\u00f4pital Necker Enfants-Malades, AP-HP, Universit\u00e9 Paris Cit\u00e9, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Louis","family":"L\u00e9ger","sequence":"additional","affiliation":[{"name":"Service de R\u00e9animation p\u00e9diatrique et n\u00e9onatale, H\u00f4pital Armand Trousseau, AP-HP, Sorbonne Universit\u00e9, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Rambaud","sequence":"additional","affiliation":[{"name":"Service de R\u00e9animation p\u00e9diatrique et n\u00e9onatale, H\u00f4pital Armand Trousseau, AP-HP, Sorbonne Universit\u00e9, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Bille","sequence":"additional","affiliation":[{"name":"Service de microbiologie, H\u00f4pital Necker Enfants-Malades, AP-HP, Universit\u00e9 Paris Cit\u00e9, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Renolleau","sequence":"additional","affiliation":[{"name":"Service de R\u00e9animation et surveillance continue m\u00e9dicochirurgicales, H\u00f4pital Necker Enfants-Malades, AP-HP, Universit\u00e9 Paris Cit\u00e9, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Marc","family":"Tr\u00e9luyer","sequence":"additional","affiliation":[{"name":"Service de microbiologie, H\u00f4pital Necker Enfants-Malades, AP-HP, Universit\u00e9 Paris Cit\u00e9, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e8s","family":"Gana","sequence":"additional","affiliation":[{"name":"Service de pharmacologie clinique, H\u00f4pital Cochin, AP-HP, Universit\u00e9 Paris Cit\u00e9, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthie","family":"Lorrot","sequence":"additional","affiliation":[{"name":"Service de pharmacologie clinique, H\u00f4pital Cochin, AP-HP, Universit\u00e9 Paris Cit\u00e9, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Grimaud","sequence":"additional","affiliation":[{"name":"Service de P\u00e9diatrie G\u00e9n\u00e9rale et Infectieuse, H\u00f4pital Armand Trousseau, AP-HP, Sorbonne Universit\u00e9, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Toubiana","sequence":"additional","affiliation":[{"name":"Service de R\u00e9animation et surveillance continue m\u00e9dicochirurgicales, H\u00f4pital Necker Enfants-Malades, AP-HP, Universit\u00e9 Paris Cit\u00e9, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathe","family":"B\u00e9ranger","sequence":"additional","affiliation":[{"name":"Service de P\u00e9diatrie G\u00e9n\u00e9rale et Infectieuse, H\u00f4pital Necker Enfants-Malades, AP-HP, Universit\u00e9 Paris Cit\u00e9, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihem","family":"Benaboud","sequence":"additional","affiliation":[{"name":"Service de R\u00e9animation et surveillance continue m\u00e9dicochirurgicales, H\u00f4pital Necker Enfants-Malades, AP-HP, Universit\u00e9 Paris Cit\u00e9, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Oualha","sequence":"additional","affiliation":[{"name":"Service de pharmacologie clinique, H\u00f4pital Cochin, AP-HP, Universit\u00e9 Paris Cit\u00e9, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,10,7]]},"reference":[{"key":"R1-20250502","doi-asserted-by":"crossref","first-page":"470","DOI":"10.18433\/jpps30927","article-title":"Population pharmacokinetic models of first choice beta-lactam antibiotics for severe infections treatment: What antibiotic regimen to prescribe in children?","volume":"23","author":"Marsot","year":"2020","journal-title":"J Pharm Pharm Sci"},{"key":"R2-20250502","doi-asserted-by":"crossref","first-page":"624639","DOI":"10.3389\/fped.2021.624639","article-title":"Model-informed precision dosing of antibiotics in pediatric patients: A narrative review.","volume":"9","author":"Abdulla","year":"2021","journal-title":"Front Pediatr"},{"key":"R3-20250502","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","article-title":"Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacologie et Th\u00e9rapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Anesth\u00e9sie et R\u00e9animation-SFAR).","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Crit Care"},{"key":"R4-20250502","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00228-023-03598-x","article-title":"Challenges of pediatric pharmacotherapy: A narrative review of pharmacokinetics, pharmacodynamics, and pharmacogenetics.","volume":"80","author":"Watanabe","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"R5-20250502","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1002\/phar.1476","article-title":"Pharmacokinetics of continuous-infusion meropenem in a pediatric patient receiving extracorporeal life support.","volume":"34","author":"Cies","year":"2014","journal-title":"Pharmacotherapy"},{"key":"R6-20250502","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/01.ccm.0000510524.47813.84","article-title":"1851: Continuous infusion of meropenem in a patient on ECMO and CRRT.","volume":"44","author":"Alqaqaa","year":"2016","journal-title":"Crit Care Med"},{"key":"R7-20250502","doi-asserted-by":"crossref","first-page":"709332","DOI":"10.3389\/fphar.2021.709332","article-title":"Population pharmacokinetics of vancomycin and meropenem in pediatric extracorporeal membrane oxygenation support.","volume":"12","author":"Zylbersztajn","year":"2021","journal-title":"Front Pharmacol"},{"key":"R8-20250502","first-page":"832","article-title":"Ceftriaxone pharmacokinetics and pharmacodynamics in 2 pediatric patients on extracorporeal membrane oxygenation therapy.","volume":"45","author":"Cervantes","year":"2023","journal-title":"Ther Drug Monit"},{"key":"R9-20250502","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1128\/AAC.01696-09","article-title":"Pharmacokinetics of cefotaxime and desacetylcefotaxime in infants during extracorporeal membrane oxygenation.","volume":"54","author":"Ahsman","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R10-20250502","first-page":"631","article-title":"Pharmacokinetics and pharmacodynamics of antibiotics in septic children treated with extracorporeal membrane oxygenation.","volume":"61","author":"Zhang","year":"2023","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"R11-20250502","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/17425255.2016.1201066","article-title":"Pharmacotherapy during pediatric extracorporeal membrane oxygenation: A review.","volume":"12","author":"Himebauch","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R12-20250502","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1016\/j.clinthera.2016.07.169","article-title":"Pharmacokinetics and dosing of anti-infective drugs in patients on extracorporeal membrane oxygenation: A review of the current literature.","volume":"38","author":"Sherwin","year":"2016","journal-title":"Clin Ther"},{"key":"R13-20250502","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD.","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R14-20250502"},{"key":"R15-20250502","author":"Lobry"},{"key":"R16-20250502","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.3390\/microorganisms9071505","article-title":"Beta-lactams toxicity in the intensive care unit: An underestimated collateral damage?","volume":"9","author":"Roger","year":"2021","journal-title":"Microorganisms"},{"key":"R17-20250502","article-title":"European Committee on Antimicrobial Susceptibility Testing: Clinical Breakpoints and Dosing of Antibiotics.","year":"2024"},{"key":"R18-20250502","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40265-018-0880-z","article-title":"Therapeutic drug monitoring of beta-lactams and other antibiotics in the intensive care unit: Which agents, which patients and which infections?","volume":"78","author":"Muller","year":"2018","journal-title":"Drugs"},{"key":"R19-20250502","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/1440-1681.12527","article-title":"Should we fear tubing adsorption of antibacterial drugs in extracorporeal membrane oxygenation? An answer for cephalosporins and carbapenems.","volume":"43","author":"Tron","year":"2016","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"R20-20250502","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/PCC.0000000000001786","article-title":"A population pharmacokinetic analysis to study the effect of extracorporeal membrane oxygenation on cefepime disposition in children.","volume":"20","author":"Zuppa","year":"2019","journal-title":"Pediatr Crit Care Med"},{"key":"R21-20250502","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/phar.1882","article-title":"Evaluation of altered drug pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation.","volume":"37","author":"Ha","year":"2017","journal-title":"Pharmacotherapy"},{"key":"R22-20250502","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJM197602052940605","article-title":"Binding of drugs to serum albumin (first of two parts).","volume":"294","author":"Koch-Weser","year":"1976","journal-title":"N Engl J Med"},{"key":"R23-20250502","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1056\/NEJM197603042941005","article-title":"Drug therapy. Binding of drugs to serum albumin (second of two parts).","volume":"294","author":"Koch-Weser","year":"1976","journal-title":"N Engl J Med"},{"key":"R24-20250502","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ijantimicag.2013.10.008","article-title":"Cefazolin plasma protein binding in different human populations: More than cefazolin\u2013albumin interaction.","volume":"43","author":"Smits","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"R25-20250502","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/11539220-000000000-00000","article-title":"The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients.","volume":"50","author":"Ulldemolins","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"R26-20250502","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/PCC.0000000000002918","article-title":"Augmented renal clearance of vancomycin in suspected sepsis: Single-center, retrospective pediatric cohort.","volume":"23","author":"Scully","year":"2022","journal-title":"Pediatr Crit Care Med"},{"key":"R27-20250502","doi-asserted-by":"crossref","first-page":"102293","DOI":"10.1016\/j.eclinm.2023.102293","article-title":"Extended infusion of \u03b2-lactams significantly reduces mortality and enhances microbiological eradication in paediatric patients: A systematic review and meta-analysis.","volume":"65","author":"Budai","year":"2023","journal-title":"EClinicalMedicine"},{"key":"R28-20250502","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1097\/CCM.0b013e3181a0054d","article-title":"A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics.","volume":"37","author":"Roberts","year":"2009","journal-title":"Crit Care Med"},{"key":"R29-20250502","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1097\/PCC.0000000000002957","article-title":"Risk factors for sepsis-associated acute kidney injury in the PICU: A retrospective cohort study.","volume":"23","author":"Ninmer","year":"2022","journal-title":"Pediatr Crit Care Med"},{"key":"R30-20250502","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40262-024-01364-5","article-title":"Have we neglected to study target-site drug exposure in children? A systematic review of the literature.","volume":"63","author":"Hermans","year":"2024","journal-title":"Clin Pharmacokinet"}],"container-title":["Pediatric Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PCC.0000000000003605","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T13:03:12Z","timestamp":1746190992000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PCC.0000000000003605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,7]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/pcc.0000000000003605","relation":{},"ISSN":["1529-7535","1947-3893"],"issn-type":[{"value":"1529-7535","type":"print"},{"value":"1947-3893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,7]]}}}